Search Results - "V. Murianni"

Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer by A. Gandini, V. Martelli, L. Belgioia, S. Puglisi, M. Cremante, V. Murianni, A. Damassi, C. Pirrone, F. Catalano, M. Grassi, L. Trevisan, S. Vagge, V. Andretta, S. Mammoliti, D. Comandini, G. Fornarini, A. Pessino, A. Pastorino, S. Sciallero, A. Puccini, A.F. Sobrero

“…Background: Patients with metastatic colorectal cancer (mCRC) carrying a deficit in the mismatch repair system/microsatellite instability (dMMR/MSI) show great…”
Get full text

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program by Rebuzzi, S.E., Signori, A., Buti, S., Banna, G.L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, D., Tortora, G., Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, F., Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, A., Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., Fornarini, G.

“…The Meet-URO score allowed a more accurate prognostication than the International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated…”
Get full text

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study by Rebuzzi, S.E., Rescigno, P., Signori, A., Brunelli, M., Galuppini, F., Vellone, V.G., Gaggero, G., Maruzzo, M., Milella, M., Vignani, F., Cavo, A., Basso, U., Catalano, F., Murianni, V., Cremante, M., Damassi, A., Llaja Obispo, M.A., Banna, G.L., Buti, S., Fornarini, G.

Get full text

445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state by Pastorino, A., Puccini, A., Martelli, V., Grassi, M., Cremante, M., Gandini, A., Puglisi, S., Catalano, F., Murianni, V., Pessino, A., Andretta, V., Mammoliti, S., Sciallero, M.S., Comandini, D., Fornarini, G., Caprioni, F., Bregni, G., Barni, S., Labianca, R., Sobrero, A.F.

Get full text

802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study by Brunelli, M., Buti, S., Rebuzzi, S.E., Milella, M., Vellone, V., Bersanelli, M., Maruzzo, M., Basso, U., Signori, A., Martelli, V., Catalano, F., Damassi, A., Murianni, V., Merler, S., Casartelli, C., Fornarini, G.

Get full text

1276P Deep molecular characterization of never smoker non-small cell lung cancer (NSCLC) patients by Dellepiane, C., De Luca, G., Tagliamento, M., Coco, S., Rossi, G., Bello, M.G. Dal, Mora, M., Zullo, L., Alama, A., Bottini, A., Sacco, G., Cella, E., Bennicelli, E., Borea, R., Murianni, V., Parisi, F., Salvi, S., Pronzato, P., Dono, M., Genova, C.

Get full text

739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b) by Stellato, M., Santini, D., Verzoni, E., De Giorgi, U., Casadei, C., Buti, S., Maruzzo, M., Murianni, V., Sbrana, A., Di Lorenzo, G., Anesi, C., Sorarù, M., Naglieri, E., De Vivo, R., Vignani, F., Grillone, F., Mucciarini, C., Roviello, G., Pignata, S., Procopio, G.

Get full text